





## 5. Ulm Meeting – Biophysics of Amyloid Formation Virtual meeting

## Virtual meeting 16 February 2021

09:00 09:30	Margaret Sunde / University of Sydney, Australia RHIM functional amyloids operating for and against microbial infection
09:30	
	<b>Meytal Landau /</b> Technion - Israel Institute of Technology, Israel Functional supramolecular structures in infectious diseases as targets and therapeutics
10:00	<b>Simon Alberti /</b> Technical University of Dresden, Germany Biomolecular condensates at the nexus of stress, aging and protein aggregation disease
10:30	Raffaele Mezzenga / ETH Zurich, Switzerland Amyloid liquid crystalline phase separation
11:00	Break
11:30	Yuji Goto / University of Osaka, Japan Breakdown of supersaturation barrier links protein folding to amyloid formation
12:00	Sheena E. Radford / University of Leeds, UK Early steps in amyloid assembly: The Achilles heel of a disease mechanism
12:30	<b>Tuomas Knowles /</b> University of Cambridge, UK Kinetics of protein aggregation
13:00	Break
14:00	Adriano Aguzzi / University Hospital Zurich, Switzerland Modifiers of prion propagation and toxicity
14:30	Mathias Jucker / University of Tübingen, Germany Seeds at pre-amyloid disease stages
15:00	<b>Bernd Bukau</b> / University of Heidelberg and German Cancer Research Center, Germany Molecular dissection of alpha-syn amyloid disaggregation by the human Hsp70 machinery
15:30	Ulrich Hartl   Max Planck Institute of Biochemistry, Germany Chaperone functions in modulating amyloid aggregation
16:00	Break
16:30	James Shorter / University of Pennsylvania, USA Combating deleterious phases in ALS/FTD
17:00	Jeffery W. Kelly   The Scripps Research Institute, USA Lessons learned from drugs that slow transthyretin amyloidosis applied to Parkinson's and Alzheimer's disease
17:30	Charles G. Glabe / University of California, Irvine, USA Endogenous human anti-amyloid antibodies that are predictive or protective for AD

## 17 February 2021 09:00 Ronald Melki / Centre National de la Recherche Scientifique, France Alpha-synuclein assemblies propagation and the molecular basis of distinct synucleinopathies Henning Stahlberg / École Polytechnique Fédérale de Lausanne, Switzerland 09:30 Cryo-EM studies alpha-synuclein fibril strains and of Lewy bodies in human brain 10:00 Sjors Scheres / MRC Laboratory of Molecular Biology, UK Seeded assembly of alpha-synuclein filaments does not replicate MSA structures 10:30 Hilal A. Lashuel / École Polytechnique Fédérale de Lausanne, Switzerland Disentangling the key determinants of Huntingtin inclusion formation and toxicity **Break** 11:00 11:30 Fabrizio Chiti / University of Florence, Italy Following TDP-43 inclusion formation in vivo using a quantitative biology approach Sara Linse / Lund University, Sweden 12:00 Secondary nucleation in amyloid formation 12:30 Per Hammarström / Linköping University, Sweden Assessing Abeta and tau fibril polymorphs in vivo and in vitro 13:00 **Break** 14:00 Jan Münch / Ulm University, Germany Towards clinical application of peptide nanofibrils as viral transduction enhancer Salvador Ventura / Universitat Autonoma de Barcelona, Spain 14:30 Alpha-helical peptides to target alpha-synuclein pathogenic species with nanomolar affinity 15:00 Jennifer C. Lee / National Heart, Lung and Blood Institute, National Institutes of Health, USA Effects of PD-related truncations on alpha-synuclein fibril formation and structure 15:30 Daniel Raleigh | Stony Brook University, USA, and University College London, UK Amylin induced beta-cell death from molecular biophysics to therapeutic applications 16:00 **Break** 16:30 Robert G. Griffin | Massachusetts Institute of Technology, USA H-detection and dynamic nuclear polarization-enhanced NMR of Abeta (1-42) fibrils 17:00 William DeGrado / University of California San Francisco, USA Sensing conformational strains of amyloids 17:30 David S. Eisenberg / University of California Los Angeles, USA Functional amyloid versus pathogenic amyloid

Organization: Marcus Fändrich & Astrid Albiez

End of the meeting

18:00